Literature DB >> 18279310

Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.

Pingwei Zhao1, Sheila Ignacio, Eric C Beattie, Mary E Abood.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder involving the selective loss of spinal cord motor neurons. Excitotoxicity mediated by glutamate has been implicated as a cause of this progressive degeneration. In this study we examined two types of receptors, the excitatory alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors (AMPARs) and inhibitory cannabinoid receptor (CB1) with respect to their localization and total expression in spinal cord motor neurons. AMPAR and CB1 represent major excitatory and inhibitory transmission input, respectively, and their expression levels on the plasma membrane have direct relevance to the vulnerability of the motor neurons to glutamatergic excitotoxicity. We used quantitative immunofluorescence microscopy to comparatively measure the total cellular expression and the synaptic localization of specific subclasses of AMPARs [as determined by the presence of the subunits glutamate receptor 1 (GluR1) or glutamate receptor 2 (GluR2)] and CB1 in spinal cord motor neurons during disease progression in a G93ASOD1 mouse model of ALS. We found an increase in synaptic GluR1 and a decrease of synaptic and total GluR2 at early ages (6 weeks, prior to disease onset). Total CB1 receptor levels were decreased at 6 weeks old. We determined the gene expression of CB1, GluR1 and GluR2 using quantitative real-time reverse transcriptase-polymerase chain reaction. The decreased synaptic and total GluR2 and increased synaptic GluR1 levels may result in increased numbers of Ca2+-permeable AMPARs, thus contributing to neuronal death. Early alterations in CB1 expression may also predispose motor neurons to excitotoxicity. To our knowledge, this is the first demonstration of presymptomatic changes in trafficking of receptors that are in direct control of excitotoxicity and death in a mouse model of ALS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279310      PMCID: PMC3991137          DOI: 10.1111/j.1460-9568.2008.06041.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  47 in total

1.  Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

Authors:  M E Abood; G Rizvi; N Sallapudi; S D McAllister
Journal:  Neurosci Lett       Date:  2001-08-31       Impact factor: 3.046

Review 2.  The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.

Authors:  Diego Centonze; Silvia Rossi; Alessandro Finazzi-Agrò; Giorgio Bernardi; Mauro Maccarrone
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

3.  Molecular and synaptic changes in the hippocampus underlying superior spatial abilities in pre-symptomatic G93A+/+ mice overexpressing the human Cu/Zn superoxide dismutase (Gly93 --> ALA) mutation.

Authors:  Alida Spalloni; Raffaella Geracitano; Nicola Berretta; Carmelo Sgobio; Giorgio Bernardi; Nicola B Mercuri; Patrizia Longone; Martine Ammassari-Teule
Journal:  Exp Neurol       Date:  2005-11-23       Impact factor: 5.330

4.  Control of synaptic strength by glial TNFalpha.

Authors:  Eric C Beattie; David Stellwagen; Wade Morishita; Jacqueline C Bresnahan; Byeong Keun Ha; Mark Von Zastrow; Michael S Beattie; Robert C Malenka
Journal:  Science       Date:  2002-03-22       Impact factor: 47.728

5.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

6.  Tumor necrosis-factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels in a subset of hippocampal pyramidal neurons.

Authors:  Fumio Ogoshi; Hong Zhen Yin; Yuvarani Kuppumbatti; Bora Song; Simin Amindari; John H Weiss
Journal:  Exp Neurol       Date:  2005-06       Impact factor: 5.330

7.  Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.

Authors:  Rohini Kuner; Anthony J Groom; Iris Bresink; Hans-Christian Kornau; Vanya Stefovska; Gerald Müller; Bettina Hartmann; Karsten Tschauner; Stefan Waibel; Albert C Ludolph; Chrysanthy Ikonomidou; Peter H Seeburg; Lechoslaw Turski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-12       Impact factor: 11.205

8.  Increased cytotoxic potential of microglia from ALS-transgenic mice.

Authors:  Patrick Weydt; Eric C Yuen; Bruce R Ransom; Thomas Möller
Journal:  Glia       Date:  2004-11-01       Impact factor: 7.452

9.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.

Authors:  Yiangos Yiangou; Paul Facer; Pascal Durrenberger; Iain P Chessell; Alan Naylor; Chas Bountra; Richard R Banati; Praveen Anand
Journal:  BMC Neurol       Date:  2006-03-02       Impact factor: 2.474

View more
  19 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

Review 3.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  NO orchestrates the loss of synaptic boutons from adult "sick" motoneurons: modeling a molecular mechanism.

Authors:  Bernardo Moreno-López; Carmen R Sunico; David González-Forero
Journal:  Mol Neurobiol       Date:  2010-12-29       Impact factor: 5.590

5.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

6.  The selective vulnerability of retinal ganglion cells in rat chronic ocular hypertension model at early phase.

Authors:  Xue-Gang Luo; Kin Chiu; Flora H S Lau; Vincent W H Lee; Ken K L Yung; Kwok-Fai So
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

Review 7.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

8.  Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a quantitative confocal analysis.

Authors:  Qing Chang; Lee J Martin
Journal:  Am J Pathol       Date:  2008-12-30       Impact factor: 4.307

Review 9.  Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS.

Authors:  Kazuhide Asakawa; Hiroshi Handa; Koichi Kawakami
Journal:  Cell Mol Life Sci       Date:  2021-03-11       Impact factor: 9.261

Review 10.  Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors:  Luigia Cristino; Tiziana Bisogno; Vincenzo Di Marzo
Journal:  Nat Rev Neurol       Date:  2019-12-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.